Sun Yat-sen University
Clinical trials sponsored by Sun Yat-sen University, explained in plain language.
-
Drug combo helps High-Risk kidney patients avoid full kidney removal
Disease control CompletedThis study tested whether giving a combination of two drugs (cadonilimab and lenvatinib) before surgery could shrink kidney tumors enough to allow a partial, kidney-sparing operation instead of full removal. It included 39 adults with clear cell kidney cancer whose tumors were la…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 29, 2026 00:50 UTC
-
New combo shows promise for tough ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that no longer responded to standard platinum chemotherapy. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants took the drugs by mouth…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 28, 2026 13:08 UTC
-
Liver cancer combo shows promise: direct chemo plus systemic drugs
Disease control CompletedThis study tested whether adding a direct liver infusion of chemotherapy (HAIC) to a standard systemic chemo plus targeted therapy and immunotherapy could help people with advanced bile duct cancer live longer without the disease getting worse. 96 adults with inoperable cancer to…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver in 30 people with advanced liver cancer that had spread into the main portal vein. The goal was to see if this approach could help patients live longer and contr…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Liver cancer study seeks best Second-Line combo after initial failure
Disease control CompletedThis study looked at 200 people with advanced liver cancer whose first treatment stopped working. Researchers compared two different drug combinations to see which worked better and was safer. The goal is to help doctors choose the best second-line treatment for these patients.
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New pain pump method may speed recovery after lung surgery
Symptom relief CompletedThis study looked at two ways to deliver pain medicine through an epidural after video-assisted lung surgery. One method gives a steady drip, the other gives small bursts on a timer. The goal was to see which helps patients recover better. 252 adults took part, and researchers me…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Apr 29, 2026 00:52 UTC
-
AI tool could revolutionize liver cancer treatment decisions
Knowledge-focused CompletedThis study used artificial intelligence to analyze data from 7,000 liver cancer patients. The goal was to create a tool that helps doctors predict which treatments—like surgery or medication—will work best for each person. The AI model looks at patient information to guide person…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Apr 29, 2026 00:50 UTC
-
Breast milk showdown: preterm vs. term – What's the difference?
Knowledge-focused CompletedThis study looked at 103 research papers to compare the nutrients in breast milk from mothers who gave birth early (preterm) versus those who gave birth at full term. The goal was to see if there are differences in energy, protein, fat, and other nutrients. The findings help doct…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Apr 26, 2026 20:02 UTC